Europe Infectious Disease In vitro Diagnostics Market Size and Forecast (2021 - 2031), Regional Share, Trend, and Growth Opportunity Analysis

The Europe Infectious Disease In Vitro Diagnostics Market is projected to grow significantly, reaching an estimated US$ 20,866.3 million by 2031, up from US$ 11,946.2 million in 2024. This growth represents a compound annual growth rate (CAGR) of 8.3% from 2025 to 2031. The market encompasses various countries, including Germany, the UK, France, Italy, Spain, Austria, Belgium, the Netherlands, Luxembourg, and the Rest of Europe, and is a crucial segment of the global diagnostics market.

The growth of the infectious disease in vitro diagnostics market in Europe is primarily driven by increased life science research and heightened government investments in testing for infectious diseases. In response to rising outbreaks of viral diseases, European governments have implemented significant measures to bolster their healthcare systems. For example, the establishment of the French National Agency for Research on AIDS and Viral Hepatitis (ANRS) in January 2021 aims to enhance research on emerging infectious diseases. Similarly, Germany's collaboration with the German Center for Infection Research (DZIF) focuses on developing innovative strategies for the prevention, diagnosis, and treatment of infectious diseases. The UK government has also aligned its strategies with the World Health Organization's (WHO) goals, particularly in addressing viral hepatitis by 2030, as highlighted by the UK Health Security Agency's (UKHSA) initiatives to combat hepatitis C, hepatitis B, and HIV.

The market segmentation reveals that by application, the largest share in 2024 was held by Hepatitis B and C, while by end user, Hospitals and Clinics dominated the market. This indicates a strong demand for diagnostics in clinical settings, where timely and accurate testing is critical for patient management.

Government initiatives aimed at raising awareness about infectious diseases and their diagnosis present significant opportunities for the in vitro diagnostics market. Public health campaigns, including immunization drives and community screenings, are increasing the utilization of diagnostic tests. National disease-control programs for conditions such as tuberculosis, HIV, hepatitis, malaria, and dengue are incorporating mass screening, which sustains demand for both centralized and point-of-care diagnostic solutions.

Moreover, governments are investing in research and development (R&D) to foster diagnostic innovation, expediting regulatory processes and encouraging public-private partnerships. Programs like the US NIH's RADx initiative and similar efforts in Europe and Asia have accelerated the development and deployment of rapid and molecular tests. In lower- and middle-income countries, WHO's Essential Diagnostics List (EDL) and initiatives like FIND and the Global Fund are prioritizing funding for high-burden disease diagnostics. The COVID-19 pandemic has further emphasized the need for robust diagnostic capabilities, leading to increased investment in national preparedness and disease surveillance.

Partnerships with international health organizations and government subsidies are enhancing access to diagnostic tools, particularly in rural and underserved regions. This supportive environment is attracting investments from diagnostic companies focused on developing and distributing innovative testing solutions tailored to local needs. Overall, government-led awareness campaigns are expected to create lucrative opportunities in the infectious disease IVD market, driving sustained demand for diagnostic innovations.

Country-wise, Germany is the largest market in Europe for infectious disease in vitro diagnostics, driven by the rising prevalence of infectious diseases and increased awareness of antimicrobial resistance (AMR). Reports from the Robert Koch Institute indicate a concerning trend in new HIV infections, prompting initiatives like Gilead Sciences' HIVISION100 to help Germany meet its UNAIDS goal of 95% HIV diagnosis by 2025.

Market players are actively pursuing both organic and inorganic growth strategies to expand their market presence. For instance, Abingdon Health plc announced an extension of its distribution agreement with Salignostics for the launch of a saliva-based pregnancy test in several European countries. Additionally, Werfen has partnered with Seegene to co-found a new company in Spain, focusing on localized diagnostic product development.

Key players in the Europe Infectious Disease In Vitro Diagnostics Market include Abbott Laboratories, F. Hoffmann-La Roche Ltd, Sysmex Corp, bioMerieux SA, Bio-Rad Laboratories Inc, QIAGEN NV, Bruker Corp, QuidelOrtho Corp, Becton, Dickinson and Co, and Danaher Corp. These companies are leveraging various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their offerings and increase market share.